DOCSLIB.ORG

Global Challenge of Antibiotic-Resistant Mycoplasma Genitalium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Challenge of Antibiotic-Resistant Mycoplasma Genitalium Global challenge of antibiotic-resistant Mycoplasma genitalium Sabine Pereyre USC EA 3671 Mycoplasmal and chlamydial infections in humans INRA - University of Bordeaux -Bordeaux University Hospital National French Reference Center for bacterial IST ECCMID, April 24th 2018 ESCMID eLibrary © by author Disclosures Travel grants from – Diagenode, Belgium – SpeeDx, Australia – Hologic, USA My laboratory has received remuneration for contract work from – bioMérieux, France – Meridian Bioscience, Europe – Diagenode, Belgium – SpeeDx, Australia – Hologic, USA ESCMID eLibrary 2 © by author M. genitalium STI agent responsible for – Non gonococcal urethritis, proctitis – Cervicitis, PID, preterm birth, spontaneous abortion – Carriage frequently asymptomatic Prevalence – Community-based population 1–3% – STI center population (high risk sexual behaviour) 4 – 38% Diagnostic – only NAAT tests – No serology – ≈ no culture antimicrobial susceptibility testing hardly achievable ESCMID eLibrary 3 © by author M. genitalium and antibiotics Intrinsic resistance to ATB targeting the cell wall (-lactams, fosfomycin, glycopeptides) and rifampicin (mutation in rpoB gene) In vitro active antibiotics – Macrolides and related antibiotics (MLSK) – Fluoroquinolones – Tetracyclines ESCMID eLibrary 4 © by author M. genitalium and tetracyclines Relative potency in vitro MIC ranges (µg/ml) Antibiotics M. genitalium M. hominis Ureaplasma spp. Tetracyclines** Doxycycline ≤0.060.01 -–0.31 0.1-2 0.02-1 Minocycline ≤0.01-0.2 0.03-1 0.06-1 MLS group BUT,Eryth rolowmyci neradication rate≤0.01 32->1 000 0.02-16 –RoxiMicrobiologicalthromycin cure of<0 doxycycline.01 : between>16 30 and 40 %0.1-2 – Not a first-line treatment Clarithromycin ≤0.01-0.06 16->256 ≤0.004-2 Azithromycin ≤0.01-0.03 4->64 0.06-4 Pereyre, AntimicrobJosa. mChemotherycin . Vaccines, 3rd edition0.01, 2016;-0.02 Jensen Antimicrob0.05Agnets-2 Chemother 2014;0.03 -Jensen4 J Eur Acad Dermatol Venereol. 2016 ESCMID eLibrary 5 Clindamycin 0.2-1 ≤0.008-2 0.2-64 Pristinamycin ≤0.01-0.02 0.1-0.5 0.1-1 Quinup risti n/ D alfo prist in ©0.05 by 0.03author-2 0.05-0.5 Ketolides Telithromycin ≤0.015 2-32 ≤0.015-0.25 Solithromycin ≤0.000000063- 0.002-0.008 0.002-0.063 0.000125 Fluoroquinolones** Ciprofloxacin 2 0.1-4 0.1-16 Ofloxacin 1-2 0.1-4 0.2-4 Levofloxacin 0.5-1 0.1-2 0.2-2 Moxifloxacin 0.03-0.06 0.06-0.125 0.125-1 Other agents Chloramphenicol 0.5-25 4225 0.4-8 Gentamicin ND 2-16 0.1-13 M. genitalium and MLSK Low MICs Antibiotics M. genitalium M. hominis Ureaplasma spp. MLSK group Erythromycin ≤0.01 32->1 000 0.02-16 Roxithromycin <0.01 >16 0.1-2 Clarithromycin ≤0.01-0.06 16->256 ≤0.004-2 Azithromycin ≤0.01-0.03 4->64 0.06-4 Josamycin 0.01-0.02 0.05-2 0.03-4 Clindamycin 0.2-1 ≤0.008-2 0.2-64 Pristinamycin ≤0.01-0.02 0.1-0.5 0.1-1 Quinupristin/ Dalfopristin 0.05 0.03-2 0.05-0.5 Telithromycin ≤0.015 2-32 ≤0.015-0.25 Solithromycin ≤0.000000063- 0.002-0.008 0.002-0.063 0.000125 ESCMID eLibraryPereyre, Antimicrob. Chemother. Vaccines, 3rd edition , 2016 6 © by author Acquired resistance to macrolides • Point mutations in domain V of 23S rRNA - Single operon encoding 16S and 23S rRNA - A2058G/C/T, A2059G/C/T, A2062G/T (E. coli numbering) high level resistance 2062 23S rRNA Domain V ESCMID eLibraryPeptidyl transferase loop © by author All M. genitalium-positive test should be followed up with an assay capable of detecting macrolide resistance- associated mutations ESCMID eLibrary 8 © by author Detection of macrolide resistance-associated mutations Amplification and sequencing of 23S rRNA – Time-consuming, not adapted to routine Published in-house methods – FRET real-time PCR (Touati et al. J. Clin. Microbiol. 2014) – HRM (High Resolution Melting curve analysis) (Twin et al. PloS One 2012) – PCR and pyrosequencing (Salado-Rasmussen et al. Clin. Infect. Dis. 2014) – Taqman PCR using forward primers complementary to 23S mutations (Wold et al. J. Eur. Acas. Dermatol. Venereol. 2015), only if Ct<32. – Taqman PCR using 3 probes and subsequent endpoint fluorescence analysis (Kristiansen et al. J. Clin. Microbiol. 2016) – Single probe PCR and melting curve analysis (Gossé et al. J. Clin. Microbiol. 2016) Commercial kits – ResistancePlusTM MG kit (SpeeDx, Australia) : multiplex real-time PCR (Le Roy, J. Clin. Microbiol. 2017) – S-DiaMGRes kit (Diagenode, Belgium) : multiplex real-time PCR Detection of Mg and 5 mutations – Others expected ESCMID eLibrary 9 © by author Prevalence of macrolide resistance in M. genitalium10 100%(26/26) 56-61% 18% 4.6-6,7% 58% 41% 57% 53% 48% 35% 29% No data 83% in MSM <10% 43-63% 10%-20% 9,8% 20%-40% 40-60% >60% 72-77% Anagrius, PloS one 2013; Tagg, J. Clin. Microbiol. 2013; Pond, Clin. Inf. Dis. 2014; Salado-Rasmussen, Clin. Inf. Dis, 2014; Kikuchi, J. Antimicrob. Chemother. 2014; Hay, Sex. Transm. Dis. 2015; Gushin, BMC Infect. Dis. 2015; Nijhuis, J. Antimicrob. Chemother. 2015; Gesink, Can. Fam. Physician, 2016; Getman, J. Clin. Microbiol. 2016; Gossé, J. Clin. Microbiol. 2016; Shipitsina, Plos One, 2017; Basu, J. Clin. Microbiol. 2017; Tabrizi, J. Clin. Microbiol. 2017; Barbera, Sex. Transm. Dis. 2017; Dumke, Diagn Microbiol infect Dis, 2016; Coorevits, J. Glob. Antimicrob. Resist. 2017; Anderson, J. Clin.ESCMIDMicrobiol. 2017; Unemo, Clin. Microbiol. Infect.2017. eLibrary © by author Treatment studies : azithromycin (AZM) 1g • Meta-analysis on the efficacy of AZM 1g for Mg treatment (Lau et al Clin. Infect. Dis. 2015) 100% 90% 83.5% 80% 67% 70% 60% The efficacy of azithromycin 1 g has 50% 40% decreased 30% 20% 10% 0% Pooled microbial cure rate (%) rate cure microbial Pooled Before 2009 Since 2009 • Selection of resistant mutants during AZM 1g treatment • AZM 1g single dose is no more the 1st line treatment Therapeutic failure if patient infected with a mutated strain Björnelius Sex Transm Infect 2008; Manhart Clin Infect Dis 2013; Mena Clin Infect Dis 2009; Schwebke CID 2011, Sena J Infect Dis 2012; Stamm Sex Transm InfectESCMID 2007; Lau Clin Infect Dis 2015; Horner Clin Infect Dis 2015;eLibrary Jensen BMC Infect Dis 2015 © by author IMPORTANT MESSAGE : Rapid increasing prevalence of macrolide resistance most likely due to widespread use of azithromycin 1g single dose Uncomplicated M. genitalium infection: - In the absence of macrolide resistance-associated mutations Azithromycin 500 mg (day 1), then 250 mg (days 2-5) 85% effective Associated with lower risk of inducing AZM R (conflicting evidence) Patients failing azithromycin 1g single dose cannot be treated successfully with extended 1.5 g AZM 12 Anagrius PLoS One 2013, Bjornelius Sex Transm Infect 2008, Falk J Antimicrob Chemother 2015, Gundevia STI 2015, Read, Clin Inf Dis 2017; Horner Sex ESCMIDTrans Ingfect 2018; Jernberg Sex Transm Infect 2008, JenseneLibrary Clin Infect 2009 © by author Uncomplicated M. genitalium infection: - Macrolide-resistant M. genitalium infection - Second line treatment for persistent M. genitalium infection Moxifloxacin 400 mg/d - 7 to 10 days Complicated M. genitalium infection (PID, epididymitis) Moxifloxacin: 400 mg - 14 days ESCMID eLibrary 13 © by author M. genitalium and fluoroquinolones Only moxifloxacin and sitafloxacin have low MICs Antibiotics M. genitalium M. hominis Ureaplasma spp. Fluoroquinolones Ciprofloxacin 2 0.1-4 0.1-16 Ofloxacin 1-2 0.1-4 0.2-4 Levofloxacin 0.5-1 0.1-2 0.2-2 Moxifloxacin 0.03-0.06 0.06-0.125 0.125-1 Sitafloxacin (Japan) 0.125 Deguchi, J Infect Chemother 2014; Pereyre, Antimicrob. Chemother. Vaccines, 3rd edition, 2016 ESCMID eLibrary 14 © by author Fluoroquinolone resistance in M. genitalium • Mutations in the bacterial target genes of fluoroquinolones - Most frequent mutations in parC (Topoisomerase IV) Primarily Ser83 and Asp87 - Rare mutations in gyrA (DNA gyrase) • Many mutations have not been evaluated by in vitro MIC determination • Molecular detection only: amplification and sequencing of target genes ESCMID eLibrary © by author Prevalence of fluoroquinolone resistance-associated mutations16 10.2% 6.2% 4.1% 20% 4.5% 10% 6% 13.6% 8% 31- 47% No data <10% 12-19% 10%-20% 20%-40% 40-60% >60% 23% Bissessor Clin Infect Dis 2015; Deguchi, Clin Infect Dis 2016; Dumke, DMID 2016; Kikuchi J Antimicrob Chemother 2014; Le Roy Emerg Infect Dis 2016; Pond Clin Infect Dis 2014; Shipitsina PLoS one 2017; Couldwell Int J STD and AIDS 2013; Gesink Can family Physian 2016; Tagg J Clin Microbiol 2013; Murray Emerg Infec Dis 2017; Barbera ESCMIDSex Transm infect 2017; Anderson, J Clin Microbiol 2017, UnemoeLibrary, Clin Microbiol Infect 2017. © by author M. genitalium fluoroquinolone treatment studies Meta-analysis on the efficacy of moxifloxacin for M. genitalium treatment – 17 studies, 252 patients 100 % 100 89 % 90 80 70 60 50 40 30 20 10 0 Before 2010 Since 2010 Pooled microbial cure rate (%) rate cure microbial Pooled ESCMID eLibraryYi et al Int J STD AIDS 2017 © by author Dual class resistance Prevalence – Japan : 17-30% – Australia : 8.6 - 9.8% – Denmark : 4.2% Mainly due to successive treatment failures of macrolides then fluoroquinolones Enormous clinical implications – No other highly effective antibiotics available What can we use as third line therapy? Murray Emerg Infect Dis 2017, Kikuchi J Antimicrobiol Chemother 2014; Le Roy Emerg Infect Dis 2016; Degushi Clin Infect Dis 2016; Kikuchi J Antimicrobiol ESCMIDChemother 2014 eLibrary 18 © by author • Third-line treatment for persistent MG infection after AZM and MXF Doxycycline 100 mg x2 daily for 14 days Pristinamycin 1 g x4 daily for 10 days ESCMID eLibrary © by author Pristinamycin MICs – AZM-resistant strains have higher MIC90 (0.5 mg/l) than AZM-susceptible strains (MIC90=0.125 mg/l) – but MICs close to the breakpoint : 1 mg/l (French society for microbiology, not dedicated to mycoplasmas) Maximum dose of 1g 4 times/day for 10 days was retained Evaluation in patients after azithromycin failure (2012-2016, Australia) – 114 persons : infection cured in 75% Option during pregnancy and in other situations where fluoroquinolones have failed or are contraindicated Not registered in many countries Renaudin et al.
Load more

Recommended publications
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Tackling Pristinamycin IIB Problems: Synthetic Studies Toward Some Fluorinated Analogs †
    Proceeding Paper Tackling Pristinamycin IIB Problems: Synthetic Studies toward Some Fluorinated Analogs † Assia Chebieb * and Chewki Ziani-Cherif Department of Chemistry, University Abou-Bekr Belkaid of Tlemcen/Laboratory of Catalysis and Synthesis in Organic Chemistry LCSCO, 13000 Tlemcen, Algeria; [email protected] * Correspondence: [email protected] † Presented at the 24th International Electronic Conference on Synthetic Organic Chemistry, 15 November–15 December 2020; Available online: https://ecsoc-24.sciforum.net/. Abstract: Streptogramins are potent antibiotics against numerous highly resistant pathogens and therefore are used in last-resort human therapy. These antibiotics are formed of both A- and B-group compounds named pristinamycins that differ in their basic primary structures. Although pristina- mycin IIB is among the most interesting antibiotics in this family, it presents numerous problems related to its chemical structure, such as instability at most pH levels, weak solubility in water, and resistance by bacteria. As a response to the need for developing new antimicrobial agents, we have designed a new analog of pristinamycin IIB, based most importantly on the introduction of fluorine atoms. We conjectured indeed that the introduced modifications may solve the above-mentioned problems exhibited by pristinamycin IIB. Our multistep synthetic approach relies on few key reac- tions, namely a Wittig reaction, a Grubbs reaction, and dihydroxy, -difluoro API (Advanced Phar- maceutical Intermediate) synthesis Keywords: streptogramins; pristinamycins IIB; fluorine Citation: Chebieb, A.; Ziani-Cherif, C. Tackling Pristinamycin IIB Problems: Synthetic Studies toward Some Fluorinated Analogs. Chem. The first antibiotic mixture of streptogramin antibiotics was isolated from the pro- Pro. 2021, 3, 107. https://doi.org/ ducer strain Streptomyces graminofaciens from a soil sample in Texas [1].
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Danmap 2006.Pmd
    DANMAP 2006 DANMAP 2006 DANMAP 2006 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark Statens Serum Institut Danish Veterinary and Food Administration Danish Medicines Agency National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark Editors: Hanne-Dorthe Emborg Danish Zoonosis Centre National Food Institute, Technical University of Denmark Mørkhøj Bygade 19 Contents DK - 2860 Søborg Anette M. Hammerum National Center for Antimicrobials and Contributors to the 2006 Infection Control DANMAP Report 4 Statens Serum Institut Artillerivej 5 DK - 2300 Copenhagen Introduction 6 DANMAP board: National Food Institute, Acknowledgements 6 Technical University of Denmark: Ole E. Heuer Frank Aarestrup List of abbreviations 7 National Veterinary Institute, Tecnical University of Denmark: Sammendrag 9 Flemming Bager Danish Veterinary and Food Administration: Summary 12 Justin C. Ajufo Annette Cleveland Nielsen Statens Serum Institut: Demographic data 15 Dominique L. Monnet Niels Frimodt-Møller Anette M. Hammerum Antimicrobial consumption 17 Danish Medicines Agency: Consumption in animals 17 Jan Poulsen Consumption in humans 24 Layout: Susanne Carlsson Danish Zoonosis Centre Resistance in zoonotic bacteria 33 Printing: Schultz Grafisk A/S DANMAP 2006 - September 2007 Salmonella 33 ISSN 1600-2032 Campylobacter 43 Text and tables may be cited and reprinted only with reference to this report. Resistance in indicator bacteria 47 Reprints can be ordered from: Enterococci 47 National Food Institute Escherichia coli 58 Danish Zoonosis Centre Tecnical University of Denmark Mørkhøj Bygade 19 DK - 2860 Søborg Resistance in bacteria from Phone: +45 7234 - 7084 diagnostic submissions 65 Fax: +45 7234 - 7028 E.
    [Show full text]
  • A New Enzyme Which Modifies Pristinamycin Iia Francois Le
    VOL. XXX NO. 8 THE JOURNAL OF ANTIBIOTICS 665 PLASMID-MEDIATED PRISTINAMYCIN RESISTANCE PAC IIA: A NEW ENZYME WHICH MODIFIES PRISTINAMYCIN IIA FRANCOIS LE GOFFIC, MARIE-LOUISE CAPMAU, DIDIER BONNET, CLAUDE CERCEAU, CLAUDE SOUSSY*, ALAIN DUBLANCHET and J. DUVAL* Centre d'Etude et de Recherche de Chimie Organique Appliquee, Centre National de la Recherche Scientifique, 94320 Thiais, France *Service de Bacteriologie , Centre Hospitalier Henri-Mondor, 94010 Creteil, France (Received for publication January 17, 1977) A wild strain of Staphylococcus aureus which inactivates a wide variety of antibiotics has been found to inactivate pristinamycin IIA, an antistaphylococcal antibiotic. This pheno- menon has been demonstrated to be plasmid mediated. The plasmid directs the biosynthesis of an acetyltransferase which is able to O-acetylate the drug. We propose to call the new enzyme PAC (IIA): Pristinamycin acetyltransferase. The pristinamycins belong to the group of "mikamycins" which are a complex of synergistic com- pounds2) identical in structure with ostreogrycin. These compounds are produced by Streptomyces pristinaespiralis and are widely used against staphylococcal infections. Pristinamycin IIA (N. W. 526) is a macrocyclic lactone containing pyrrolidine and oxazole rings with structure as shown in Fig. Ia. It is identical with mikamycin A, ostreogrycin A, streptogramin A, vernamycin A, PA II4A1 and virginiamycin M. Pristinamycin IIB (M. W. 528), ostreogrycin G or virginiamycin M2 has the structure with the 4-2, 3 bond saturated (Fig. lb). The group B antibiotic is a depsipeptide (Fig. 2) and includes pristinamycin IA, mikamycin B, streptogramin B, PA II4B and ostreogrycin B. Other derivatives of this B group are also present in the fermentation broth of the Streptomyces pristinaespiralis producing strain.
    [Show full text]
  • Synercid I.V
    NDA 50-747/S-008 NDA 50-748/S-008 Page 3 Synercid® I.V. (quinupristin and dalfopristin for injection) One of Synercid’s approved indications is for the treatment of patients with serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium (VREF) bacteremia. Synercid has been approved for marketing in the United States for this indication under FDA’s accelerated approval regulations that allow marketing of products for use in life-threatening conditions when other therapies are not available. Approval of drugs for marketing under these regulations is based upon a demonstrated effect on a surrogate endpoint that is likely to predict clinical benefit. Approval of this indication is based upon Synercid’s ability to clear VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate endpoint. There are no results from well-controlled clinical studies that confirm the validity of this surrogate marker. However, a study to verify the clinical benefit of therapy with Synercid on traditional clinical endpoints (such as cure of the underlying infection) is presently underway. DESCRIPTION Synercid® (quinupristin and dalfopristin powder for injection) I.V., a streptogramin antibacterial agent for intravenous administration, is a sterile lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin (derived from pristinamycin I) and dalfopristin (derived from pristinamycin IIA) in the ratio of 30:70 (w/w). Quinupristin is a white to very slightly yellow, hygroscopic powder. It is a combination of three peptide macrolactones. The main component of quinupristin (>88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­ 5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio] methyl]-12H-pyrido[2,1-f]pyrrolo-[2,1­ l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.
    [Show full text]
  • Protein Synthesis Inhibitors Lecture Outline
    Protein Synthesis Inhibitors • Macrolides - Lincosamides • Aminoglycosides • Tetracyclines • Chloramphenicol • Oxazolidinones • Streptogramins Lecture Outline • Description of protein synthesis - translation • Antibiotics – Structure - function - classification – Mechanism(s) of action – Mechanism(s) of resistance – Spectrum of activity/Indications for use – Pharmacology – Toxicity • Clinical examples 1 Overview of Translation (1) Initiation: • 30S binds RBS of mRNA • AA binds tRNA using aminoacyl-tRNA synthetase • IF2 and fmet-tRNA binds 30S at P site • 50S binds complex 70S resulilting in th e f ormati on of the initiation complex Overview of Translation (2) Initiation – tRNA + AA binds translation elongation factor – Enters ribosome and attaches at the A site 2 Overview of Translation (3) Amino Acid Transfer – Petidyltransferase on 50S ribosome attaches the next AA to the polypeptide – Met added to Leu at A site Overview of Translation (4) Elongation tRNA moved to P site by EF-G creating room at A site for next tRNA Translation termination Occurs at nonsense codon sites e.g. UAA Release factors Ribosome dissociates 3 Mechanisms of Action - Protein Synthesis Inhibitors Macrolides • Broad spectrum antibiotics • Original agent: erythromycin • Azalides: azithromycin and clarithromycin – seltdtiilected antimicrobi bildhal and pharmacoki kitinetic advantages 4 Large 14 member macrolactone ring with one or more deoxy sugars attached. Inhibits formation of 50S ribosome blocking trans- peptidation or translocation. Large 14 member lactone ring
    [Show full text]
  • Update on the Management of Antibiotic Allergy Bernard Yu-Hor Thong*
    Review Allergy Asthma Immunol Res. 2010 April;2(2):77-86. doi: 10.4168/aair.2010.2.2.77 pISSN 2092-7355 • eISSN 2092-7363 Update on the Management of Antibiotic Allergy Bernard Yu-Hor Thong* Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Drug allergy to antibiotics may occur in the form of immediate or non-immediate (delayed) hypersensitivity reactions. Immediate reactions are usual- ly IgE-mediated whereas non-immediate hypersensitivity reactions are usually non-IgE or T-cell mediated. The clinical manifestations of antibiotic allergy may be cutaneous, organ-specific (e.g., blood dyscracias, hepatitis, interstitial nephritis), systemic (e.g., anaphylaxis, drug induced hypersen- sitivity syndrome) or various combinations of these. Severe cutaneous adverse reactions manifesting as Stevens Johnson syndrome or toxic epider- mal necrolysis (TEN) may be potentially life-threatening. The management of antibiotic allergy begins with the identification of the putative antibiot- ic from a detailed and accurate drug history, complemented by validated in-vivo and in-vitro allergological tests. This will facilitate avoidance of the putative antibiotic through patient education, use of drug alert cards, and electronic medical records with in-built drug allergy/adverse drug reaction prescription and dispensing checks. Knowledge of the evidence for specific antibiotic cross-reactivities is also important in patient education. Apart from withdrawal of the putative antibiotic, immunomodulatory agents like high-dose intravenous immunoglobulins may have a role in TEN.
    [Show full text]
  • Ribosome Protection by Antibiotic Resistance ATP-Binding Cassette Protein
    Ribosome protection by antibiotic resistance ATP-binding cassette protein Weixin Sua,b,1, Veerendra Kumarc,1, Yichen Dingd,1, Rya Eroa,b,2, Aida Serraa, Benjamin Sian Teck Leea, Andrew See Weng Wongb, Jian Shie, Siu Kwan Szea, Liang Yanga,d,2, and Yong-Gui Gaoa,b,c,2 aSchool of Biological Sciences, Nanyang Technological University, Singapore 637551; bInstitute of Structural Biology, Nanyang Technological University, Singapore 639798; cInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673; dSingapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551; and eCentre for BioImaging Sciences, National University of Singapore, Singapore 117557 Edited by Peter B. Moore, Yale University, New Haven, CT, and approved April 11, 2018 (received for review February 23, 2018) The ribosome is one of the richest targets for antibiotics. Unfortu- peptide bond formation that underlies translation arrest (10, 11). nately, antibiotic resistance is an urgent issue in clinical practice. However, certain oligopeptides are believed to lead to drug re- Several ATP-binding cassette family proteins confer resistance to sistance by “flushing out” the macrolides while passing through ribosome-targeting antibiotics through a yet unknown mechanism. the NPET (13, 14). Therefore, the fate of the macrolide-bound Among them, MsrE has been implicated in macrolide resistance. Here, ribosome is determined by the dynamic interactions among the we report the cryo-EM structure of ATP form MsrE bound to the bound drug, the PTC, and the sequence specificity of the emerging ribosome. Unlike previously characterized ribosomal protection pro- oligopeptide chain (5, 15). It should be noted, however, that teins,MsrEisshowntobindtoribosomal exit site.
    [Show full text]
  • Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: a Review
    chemosensors Review Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: A Review Eduardo C. Reynoso 1 , Serena Laschi 2, Ilaria Palchetti 3,* and Eduardo Torres 1,4 1 Ciencias Ambientales, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [email protected] (E.C.R.); [email protected] (E.T.) 2 Nanobiosens Join Lab, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy; [email protected] 3 Dipartimento di Chimica, Università degli Studi di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy 4 Centro de Quìmica, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico * Correspondence: ilaria.palchetti@unifi.it Abstract: The indiscriminate use and mismanagement of antibiotics over the last eight decades have led to one of the main challenges humanity will have to face in the next twenty years in terms of public health and economy, i.e., antimicrobial resistance. One of the key approaches to tackling an- timicrobial resistance is clinical, livestock, and environmental surveillance applying methods capable of effectively identifying antimicrobial non-susceptibility as well as genes that promote resistance. Current clinical laboratory practices involve conventional culture-based antibiotic susceptibility testing (AST) methods, taking over 24 h to find out which medication should be prescribed to treat the infection. Although there are techniques that provide rapid resistance detection, it is necessary to have new tools that are easy to operate, are robust, sensitive, specific, and inexpensive. Chemical sensors and biosensors are devices that could have the necessary characteristics for the rapid diag- Citation: Reynoso, E.C.; Laschi, S.; nosis of resistant microorganisms and could provide crucial information on the choice of antibiotic Palchetti, I.; Torres, E.
    [Show full text]